Trial reportDrug design, development and therapy2026
ED95 of Ciprofol Combined with Esketamine or Sufentanil in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Dose-Finding and Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Age-Stratified EDDrug design, development and therapy · 2026Article
- Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Letter].Drug design, development and therapy · 2026Article
- Equipotent Doses and ED95 Extrapolation: Methodological Concerns in Trials of Ciprofol-Esketamine/Sufentanil for Elderly ESD [Response to Letter].Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to estimate the 95% effective dose (ED95) of ciprofol when combined with esketamine or sufentanil in elderly patients undergoing endoscopic submucosal dissection (ESD), and to explore the associated clinical and safety profiles of these sedation strategies. Methods: This study was conducted in two phases. In Phase 1, 44 patients aged 65-80 years undergoing ESD were randomized to receive ciprofol combined with esketamine (group E) or sufentanil (group S). Dixon's up-and-down method was used to characterize the dose-response relationship of ciprofol, and ED95 values were derived as model-based estimates. In Phase 2, 68 patients were randomized to group E or group S. Phase 2 was designed as an exploratory randomized comparison, and intraoperative parameters, hemodynamic variables, and postoperative outcomes were recorded. Results: Based on model-based analysis, the estimated ED95 of ciprofol combined with esketamine was 0.276 mg/kg (95% CI: 0.264-0.349), while that combined with sufentanil was 0.244 mg/kg (95% CI: 0.236-0.282). No significant differences were observed between the two groups in the proportion of patients requiring rescue sedation or analgesia ( Conclusion: Ciprofol combined with esketamine or sufentanil showed different clinical and hemodynamic profiles in elderly patients undergoing ESD. These findings were derived from an exploratory analysis and should be interpreted as strategy-specific rather than evidence of superiority. The longer time to full alertness with esketamine indicates a potential trade-off. Trial Registration: Chictr.org.cn; identifier: ChiCTR2500102341.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.